-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 4, China Resources Shuanghe stated that it had received the "Drug Registration Certificate" (Certificate Number: 2021S00561) for Parecoxib Sodium for Injection issued by the National Medical Products Administration, and the drug was approved for production
.
This medicine is used for short-term treatment of pain after surgery
.
The original parecoxib sodium for injection was jointly developed by Pfizer and Pharmacia.
It was first launched in Europe in March 2002 under the trade name "Dynastat".
It was approved to be marketed in China in May 2008 under the trade name "Tenai".
.
So far, the drug has been marketed in more than a dozen countries including the European Union and China
According to the global drug sales database of 71 countries, in 2020, the global sales of parecoxib sodium for injection will be 269 million US dollars
.
Among them, "Dynastat" global sales of 121 million US dollars